{"id":"adh-1-and-carboplatin","safety":{"commonSideEffects":[{"rate":"30-40%","effect":"Neutropenia"},{"rate":"20-30%","effect":"Thrombocytopenia"},{"rate":"20-30%","effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"ADH-1 is an angiogenesis inhibitor that works by targeting vascular endothelial growth factor (VEGF), while carboplatin is a platinum-based chemotherapy drug that interferes with DNA replication.","oneSentence":"Antiangiogenic and platinum-based chemotherapy","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T05:49:58.515Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT00390676","phase":"PHASE1","title":"A Study of ADH 1 in Combination With Carboplatin, or Docetaxel or Capecitabine","status":"COMPLETED","sponsor":"Adherex Technologies, Inc.","startDate":"2006-11","conditions":"Neoplasms","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"ADH -1 and carboplatin","genericName":"ADH -1 and carboplatin","companyName":"Adherex Technologies, Inc.","companyId":"adherex-technologies-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Antiangiogenic and platinum-based chemotherapy Used for Non-small cell lung cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}